Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Supernus Pharmaceuticals Inc SUPN

Healthcare Drug Manufacturers - Specialty & Generic
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes products for the treatment of central nervous system (CNS) diseases in the United States. The company offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's... see more

Current News (NDAQ:SUPN)

Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 24, 2026

GlobeNewswire 2 days ago

Supernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics Virtual Conference

GlobeNewswire December 3, 2025

Supernus Pharmaceuticals to Participate in the Piper Sandler 37th Annual Healthcare Conference

GlobeNewswire November 21, 2025

Supernus to Participate in the 2025 Jefferies Global Healthcare Conference in London

GlobeNewswire November 12, 2025

Supernus Announces Third Quarter 2025 Financial Results

GlobeNewswire November 4, 2025

Supernus Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025

GlobeNewswire October 21, 2025

Biogen Receives European Commission Approval for ZURZUVAE® (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe

GlobeNewswire September 17, 2025

Supernus Pharmaceuticals to Participate in September Investor Conferences

GlobeNewswire August 27, 2025

Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics

GlobeNewswire July 31, 2025
View More News ››

Opinion & Analysis (NDAQ:SUPN)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:SUPN)

Supernus Pharmaceuticals, Inc. (SUPN): Navigating Challenges

http://beyondspx.com/2024/08/01/supernus-pharmaceuticals-inc-supn-navigating-challenges-driving-growth-and-advancing-a-robust-pipeline/
MikeTester - August 1, 2024

watching this one for

a possible purchase this spring,it's getting close to its decade low from my charts and it does have almost a billion dollars cash,so...
coolfooldumbguy - February 26, 2020
View more Bullboard ››

Alvopetro Energy Ltd.

Alvopetro Energy Ltd.

Alvopetro Energy Ltd. engages in the acquisition, exploration, development, and production of hydrocarbons in Brazil and ...
View More »

Podcasts